| Literature DB >> 35910337 |
Salma Mesmoudi1,2,3,4, Colline Lapina2,3,4,5, Mathieu Rodic3, Denis Peschanski1,2,3.
Abstract
As the COVID-19 pandemic continues to unfold, numerous neurological symptoms emerge. The literature reports more and more manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) related to headache, dizziness, impaired consciousness, cognitive impairment, and motor disorders. Moreover, the infection of SARS-CoV-2 may have a durable neurological impact. ACE2/TMPRSS2 is the main entry point into cells for some strains of coronaviruses (CoVs), including SARS-CoV-2, which uses it to target the central nervous system (CNS). The aim of this study was to characterize the scope of the potential complex impact of a SARS-CoV-2 infection in the brain. It concerns different scales: the topographic, cognitive, sensorimotor, and genetic one. We investigated which cognitive and sensorimotor functions are associated with the brain regions where ACE2/TMPRSS2 is overexpressed, hypothesising that they might be particularly affected by the infection. Furthermore, overexpressed genes in these regions are likely to be impacted by COVID-19. This general understanding is crucial to establish the potential neurological manifestations of the infection. Data on mRNA expression levels of genes were provided by the Allen Institute for Brain Science (AIBS), and the localisation of brain functions by the LinkRbrain platform. The latter was also used to analyze the spatial overlap between ACE2/TMPRSS2 overexpression, and either function-specific brain activations or regional overexpression of other genes. The characterisation of these overexpressed genes was based on the GeneCards platform and the gene GSE164332 from the Gene Expression Omnibus database. We analysed the cognitive and sensorimotor functions whose role might be impaired, of which 88 have been categorised into seven groups: memory and recollection, motor function, pain, lucidity, emotion, sensory, and reward. Furthermore, we categorised the genes showing a significant increase in concentration of their mRNAs in the same regions where ACE2/TMPRSS2 mRNA levels are the highest. Eleven groups emerged from a bibliographical research: neurodegenerative disease, immunity, inflammation, olfactory receptor, cancer/apoptosis, executive function, senses, ischemia, motor function, myelination, and dependence. The results of this exploration could be in relation to the neurological symptoms of COVID-19. Furthermore, some genes from peripheral blood are already considered as biomarker of COVID-19. This method could generate new hypotheses to explore the neurological manifestations of COVID-19.Entities:
Keywords: ACE2; COVID-19; LinkRbrain; SARS-CoV-2; TMPRSS2; multi-data integration; neurological symptom
Year: 2022 PMID: 35910337 PMCID: PMC9326261 DOI: 10.3389/fnint.2022.756604
Source DB: PubMed Journal: Front Integr Neurosci ISSN: 1662-5145
FIGURE 12D and 3D visualisations of ACE2 (in blue) and TMPRSS2 (in magenta) mRNA overexpressions in the brain. The differences in 3D visualisation color intensity result from the transparency of the brain and the juxtaposition of several layers.
Cognitive and sensorimotor functions activating the same regions where ACE2/TMPRSS2 mRNAs are overexpressed, clustered by groups.
| Memory and recollection | Motor function | Pain | Lucidity | Emotion | Sensory | Reward |
| memory | rapid eye movement | pain perception | alertness | emotional modulation | visuomotor control | reward |
| episodic memory | ankle | pain intensity | navigation | fear conditioning | complex visual scenes | reward processing |
| recall | movement execution | evoked pain | visuospatial task | disgust | auditory discrimination | monetary rewards |
| visuospatial working memory | finger movements | painful stimuli | anticipation | pleasure | sensorimotor integration | rewarded responses |
| associative memory | motor function | pain control | task execution | fear | odour | rewarding stimuli |
| consolidation | movement sequences | pain unpleasantness | top down attentional control | fearful expressions | somatosensory stimulation | |
| memory storage | overt speech | non-painful | goal directed action | love | ||
| spatial memory | leg | phasic pain | mental rotation | disgust and fear | ||
| emotional memories | motor control | Pain representation | higher order cognitive | facial expressions of disgust | ||
| memory processes | motor performance | divided attention | aggression | |||
| short term memory | bimanual coordination | imagination | unpleasant stimuli | |||
| semantic retrieval task | muscle activity | introspection | pleasantness | |||
| false recognition | flexion | serial order | threat | |||
| familiarity | limb | sequence learning | aversive stimuli | |||
| subsequent recognition | left foot | semantic integration | noxious stimulus | |||
| declarative memory | right hand | interoceptive awareness | danger | |||
| explicit memory | foot movements | |||||
| movement complexity | ||||||
| passive movement | ||||||
| grip force | ||||||
| motor programs | ||||||
| simple motor task | ||||||
| left hand | ||||||
| movement initiation | ||||||
| wrist |
FIGURE 2Graphs portraying the regions where the ACE2 (in blue) and TMPRSS2 (in magenta) are the overexpressed and their highest correlated functions. The blue or magenta links connect “ACE2” or “TMPRSS2” network with their correlated tasks. The gray links connect tasks with each other. Each graph shows the 20 most correlated functions/regions. The complete lists of functions and regions are in the Supplementary Materials.
Genes co-expressed with ACE2/TMPRSS2, clustered by groups.
| Neurodegenerative disease and behaviour | Immunity | Inflammation | Olfactory receptor | Cancer/Apoptosis | Executive function | Sennses | Ischemia | Motor function | Myelination | Dependence |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| FGA |
| ||
|
|
|
|
|
| GPR110 | TRIM55 | ||||
|
|
|
|
|
| FRMD7 | F2RL3 | ||||
|
|
|
|
| CD248 | CLDN14 | |||||
|
|
| TRIM55 | XAGE3 | GJB3 | ||||||
|
|
| MEP1B | NCR1 | TMC3 | ||||||
|
|
| IL18RAP | HES2 | CST9L | ||||||
|
|
| STX11 | MACC1 | |||||||
|
|
| NOXO1 | FGF23 | |||||||
|
|
| LGALS17A | MUC16 | |||||||
|
|
| F2RL3 | CHST4 | |||||||
|
|
| IL22RA2 | ANAPC1 | |||||||
|
|
| PDCD1LG2 | ||||||||
|
|
| TERT | ||||||||
| LYZ |
| |||||||||
| ZNF705D |
| |||||||||
| DIO1 |
| |||||||||
| CAPN9 |
| |||||||||
| GPR84 |
| |||||||||
| UBTFL1 |
| |||||||||
| ALDH3A1 |
| |||||||||
| VDR |
| |||||||||
| NOXO1 |
| |||||||||
|
| ||||||||||
|
| ||||||||||
|
|
Pathways where our co-expressed mRNA are involved.
| Pathways | Genes |
| Keratinization and developmental biology | KRTAP13-2, KRT23, KRT28, PRDM14 |
| Signalling by Rho GTPases and cell cycle | CENPA, NOXO1, SKA1 |
| Coagulation pathway | FGA |
| Immune response IFN alpha/beta signalling pathway | IFNA16, IL4, IL28B |
| PI3K/Akt signalling and tyrosine kinases/adaptors | MACC1 |
| Defective GALNT12 causes colorectal cancer 1 (CRCS1) | MUC17, MUC16 |
| RNA Polymerase I Promoter Opening and Macrophage markers | LYZ |
| Transport glucose, diseases of glycosylation | MUC17, BEST2, MUC16, LDHAL6B, FXYD3 |
| Innate immune system | CLDN14, GPR84, C4BPA, PDCD1LG2, IL22RA2, DSG1, KLRF1, TRIM38 |
| Signalling by GPCR | GPR84, CXCR6, CST9L, NMUR2, NOXO1, OR2J3, CMA1, TAS2R1, OR5B2, OR10G7, OR11H4, C3AR1 |
| Downstream signalling of activated FGFR2 | FGF23 |
| Phospholipase-C pathway | FGF23, GRAP2 |
| Metapathway biotransformation | ALDH3A1, UGT2A3, DPEP1 |
| Cyclophosphamide pathway, pharmacodynamics | ALDH3A1 |
| Nuclear receptors in lipid metabolism and toxicity and gene expression gene expression | VDR |
| ERK signalling | IL4, ROR2, PTK7 |
| Peginterferon alpha-2a/peginterferon alpha-2b pathway (Hepatocyte), pharmacodynamics | IL28B |
| Toll-like receptor signalling pathways | IL28B, CD180 |
| Peptide ligand-binding receptors | CXCR6, GPHB5, CST9L, NMUR2, F2RL3, OR2J3, TAS2R1, GRM6, C3AR1 |
| Creation of C4 and C2 activators | C4BPA, C9 |
| Activation of cAMP-dependent PKA | MEP1B, PTK7 |
| Signal transduction_PKA signalling signal transduction_PKA signalling | MEP1B |
| Immune response IL-23 signalling pathway and IL12 signalling mediated by STAT4IL12 signalling mediated by STAT4 | IL18RAP |
| Metabolism of proteins | CHST4 |
| O-linked glycosylation of mucins | CHST4 |
| Development and heterogeneity of the ILC family and IL-17 family signalling pathways | IL25 |
| Activated TLR4 signalling | CD180 |
| Response to elevated platelet cytosolic Ca2+ and cell surface interactions at the vascular wall. | FCAMR |
| Class I MHC mediated antigen processing | PDCD1LG2 |
| Complement pathway | C9 |
| Apoptotic cleavage of cellular proteins | DSG1 |
| Apoptotic pathways in synovial fibroblasts | TERT |
| Apoptosis and autophagy and ATF-2 transcription factor network | SERPINB5 |
| Signalling by Wnt | TERT ROR2 |
| Nicotine pathway (dopaminergic neuron), pharmacodynamics | STX11 |
| Triacylglycerol degradation and lipoprotein metabolism | PNLIPRP3 |
| Glucuronidation | UGT2A3 |
| Transport of mature transcript to cytoplasm and cleavage of growing transcript in the termination region | LUZP4 |
| G-AlphaQ signalling | F2RL3 |
| TGF-beta pathway | IL22RA2 |
| Eicosanoid synthesis | DPEP1 |
| Cholesterol and sphingolipids transport | APOL5 APOL4 |
| Recycling to plasma membrane in lung (normal and CF) | APOL5 APOL4 |
| Statin pathway–generalised, pharmacokinetics, and farnesoid X receptor | ABCB11 |
| Neuropathic pain-signalling in dorsal horn neurons | KCNK5, GRM6 |
| Sweet taste signalling | KCNK5, CNGA4 |
| Pyruvate metabolism and citric acid (TCA) cycle | LDHAL6B |
| Immune response_Oncostatin M signalling | OSMR |
| G-protein signalling Ras family GTPases in kinase cascades (scheme) | OSMR |
| Class I MHC mediated antigen processing and presentation | KLRF1 |
| CREB pathway and ion channel transport | HTR3C FXYD3 |
| Regulation of TP53 activity and DNA damage response (only ATM dependent). | TP53 |
| Aminoglycoside ototoxicity pathway, adverse drug reaction | TMC2 |
| IL-2 signalling pathway and NF-kappaB signalling | IKZF3 |
| Organelle biogenesis and maintenance | CNGA4 |
| JNK signalling in the CD4+ TCR | GRAP2 |
| Histidine, lysine, phenylalanine, tyrosine, proline, and tryptophan catabolism and amino acid metabolism | HAL, HGD |
| Articular cartilage extracellular matrix | HYAL4 |
| Embryonic and induced pluripotent stem cells and lineage-specific markers and cardiac progenitor differentiation | ZFP42 |
| Transport of glucose and other sugars, bile salts and organic acids, metal ions, and amine compounds | FXYD3 |
| Development and heterogeneity of the ILC family and innate lymphoid cells differentiation | TSLP |
| Integrin pathway and phospholipase-C pathway. LM | LAMC2 |
| Development slit-robo signalling and G-beta gamma signalling | GJB3 |
| Interferon gamma signalling | TRIM38 |